A Phase 1 interventional study of Epaminurad 9 mg and C2406 in Healthy Volunteers, sponsored by JW Pharmaceutical. Completed at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by JW Pharmaceutical · Phase 1, Interventional, and Treatment
A Phase 1 Study to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and C2406 in Healthy Volunteers
JW Pharmaceutical is the lead sponsor of 75 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Clinical examination
Epaminurad 9mg, C2406 0.6mg
Drug: Epaminurad 9 mg · Drug: C2406
Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
Area under the plasma concentration versus time curve (AUC)
To evaluate the AUC of Epaminurad and C2406
Time frame: 7 days
Peak plasma concentrations (Cmax)
To evaluate the Cmax of Epaminurad and C2406
Time frame: 7 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
JW Pharmaceutical